Author | Joel M. Gelfand, MD, MSCE, FAAD

Drs Roy M. Fleischmann and Joel M. Gelfand discuss addressing patient concerns to biosimilars and provide take-home messages to clinicians utilizing biosimilars.

Roy M. Fleischmann, MD, and Joel M. Gelfand, MD, MSCE, FAAD, address the importance of clinician confidence in biosimilars.

An expert rheumatologist and a dermatologist discuss challenges to bringing biosimilars to the United States.

Expert rheumatologist and dermatologist, Drs Roy M. Fleischmann and Joel M. Gelfand, discuss the impact of switching patients to biosimilars.

Drs Roy M. Fleischmann and Joel M. Gelfand discuss the roles of biosimilars and how to assess efficacy once a patient is switched to a biosimilar.

Roy M. Fleischmann, MD, and Joel M. Gelfand, MD, MSCE, FAAD, discuss the impact of biosimilars on payers, health care systems, and patients.